<DOC>
	<DOCNO>NCT01515280</DOCNO>
	<brief_summary>The aim study patient take part Clinical trial- : A Multicentre , Double-Blind , Placebo-Controlled , Pivotal Study Efficacy Safety Oral Theobromine Management Cough . Complete Hull Airway Reflux Questionnaire ( HARQ ) randomisation repeat questionnaire end 14 day treatment period . The investigator hope demonstrate clinically significant change HARQ score least 16 point treatment . Furthermore investigator would hope show significantly improve HARQ score patient BC036 arm study compare placebo arm .</brief_summary>
	<brief_title>Hull Airway Reflux Questionnaire Scores Following Cough Treatment</brief_title>
	<detailed_description />
	<mesh_term>Cough</mesh_term>
	<criteria>1 . Male/females meet eligibility criterion study : A Multicentre , DoubleBlind , PlaceboControlled , Pivotal Study Efficacy Safety Oral BC1036 Management Cough . 2 . Willing able comply study procedures 3 . Able provide write informed consent participate 1 . Any subject meeting exclusion criterion study `` A Multicentre , DoubleBlind , PlaceboControlled , Pivotal Study Efficacy Safety Oral BC1036 Management Cough . '' Will exclude study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>chronic cough</keyword>
</DOC>